menu
    • menu
    [{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Lupagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Lupagen","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Lupagen"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series C Financing","leadProduct":"Rapamycin","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Double Point Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Umoja Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCRI-E2CAR_EGFRtv1","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Umoja Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Umoja Biopharma"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"UB-TT170","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ SoftBank Vision","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ SoftBank Vision"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":1.4399999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.4399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV200","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series A Financing","leadProduct":"VivoCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ MPM Capital"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Umoja Biopharma"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"2","companyTruncated":"Umoja Biopharma \/ IASO Bio"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Ozette Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Umoja Biopharma"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"Umoja Biopharma \/ IASO Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Umoja Biopharma

    Menu

    Umoja Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV400,Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Double Point Ventures

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Umoja Raises $100M Series C to Advance in Vivo CAR-T Therapies

                            Details : The proceeds from the financing will enable Umoja to advance its vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in cancer and Large B-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 14, 2025

                            Lead Product(s) : UB-VV400,Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Double Point Ventures

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona Biosciences and Umoja Partner To Develop in Vivo CAR-T Therapies

                            Details : The collaboration leverages Nona's proprietary fully human-heavy chain-only antibody technology to produce novel in vivo generated CAR-T cell therapy drug candidates for oncology and autoimmunity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Umoja Biopharma Receives FDA IND Clearance for UB-VV111 in Blood Cancers

                            Details : UB-VV111 is a CD19-directed in-situ generated CAR-T cell therapy candidate, which is being evaluated for the treatment of patients with hematologic malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 31, 2024

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

                            Details : UB-VV111 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 30, 2024

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : $1,440.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Umoja Biopharma Announce Collaboration to Develop Novel CAR-T Cell Therapies

                            Details : The collaboration aims for Abbvie to focus on the CD19-directed in-situ generated CAR-T cell therapy candidates, which include UB-VV111 for the treatment of hematologic malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : UB-VV111

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : $1,440.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : IASO Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Iaso Bio Announces New Development Partnership with Umoja Biopharma for Therapies

                            Details : IASO Bio will receive exclusive access to Umoja's synthetic cytokine receptor technology for developing two ex vivo iPSC-derived chimeric antigen receptor-bearing cell therapies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : IASO Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Ozette Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ozette Technologies Announces New Collaboration with Umoja Biopharma to Accelerate Biomarker Discovery in Prec...

                            Details : Under the collaboration, Umoja will leverage Ozette Endpoints™ and Ozette Discovery™ to enable both companies' multidisciplinary scientific and bioinformatic teams to collaborate and expand the benefits of CAR T-cell immunotherapy to patients in need...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Ozette Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : IASO Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration

                            Details : The collaboration will focus on bringing off-the-shelf therapies to patients with hematological malignancies, initially acute myeloid leukemia (AML), with a goal of increasing patient accessibility.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 21, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : IASO Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV200

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies ...

                            Details : The presentations will highlight Umoja’s complementary cell therapy platforms for in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 19, 2022

                            Lead Product(s) : UB-VV200

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Umoja Biopharma

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-VV100

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enab...

                            Details : New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™), UB-VV100 as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACRTM synthetic cytokine receptor system.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 28, 2022

                            Lead Product(s) : UB-VV100

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth